5245582026-01-012026-03-315245582026-03-315245582025-03-315245582025-04-012026-03-315245582026-01-012026-03-31in-capmkt:OtherExpenses1Member5245582026-01-012026-03-31in-capmkt:OtherExpenses2Member5245582025-04-012026-03-31in-capmkt:OtherExpenses1Member5245582025-04-012026-03-31in-capmkt:OtherExpenses2Member5245582026-03-31OtherNoncurrentFinancialAssetsDomain15245582026-03-31OtherNoncurrentAssetsDomain15245582026-03-31OtherNoncurrentAssetsDomain25245582026-03-31OtherNoncurrentAssetsDomain35245582026-03-31OtherNoncurrentAssetsDomain45245582026-03-31OtherCurrentFinancialAssetsDomain15245582026-03-31OtherCurrentFinancialAssetsDomain25245582026-03-31OtherCurrentAssetsDomain15245582026-03-31OtherCurrentAssetsDomain25245582026-03-31OtherCurrentAssetsDomain35245582026-03-31OtherCurrentAssetsDomain45245582026-03-31OtherCurrentAssetsDomain55245582026-03-31OtherNoncurrentFinancialLiabilitiesDomain15245582026-03-31OtherCurrentFinancialLiabilitiesDomain15245582026-03-31OtherCurrentFinancialLiabilitiesDomain25245582026-03-31OtherCurrentFinancialLiabilitiesDomain35245582026-03-31OtherCurrentFinancialLiabilitiesDomain45245582026-03-31OtherCurrentFinancialLiabilitiesDomain55245582026-03-31OtherCurrentFinancialLiabilitiesDomain65245582026-03-31OtherCurrentFinancialLiabilitiesDomain75245582026-03-31OtherCurrentLiabilitiesDomain15245582026-03-31OtherCurrentLiabilitiesDomain25245582026-03-31OtherCurrentLiabilitiesDomain35245582026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15245582026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25245582025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15245582025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25245582026-01-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15245582025-04-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15245582026-01-012026-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares524558NEULANDLABNOTLISTEDINE794A01010NEULAND LABORATORIES LIMITEDMain BoardEquity2025-04-012026-03-312026-05-122026-04-20INRLakhsQuarterlyFourth quarterSingle segmentManufacturing of Active Pharmaceuticals2026-05-1214:15:002026-05-1215:45:00trueCash Flow IndirectDeclaration of unmodified opinion2026-01-012026-03-31AuditedConsolidated77625030001245820007887085000230788700003850210009847170007205100025088900010115720005012137000287494800002874948000768221000-199990007482220000212672600000002126726000123660002139092000212672600002139092000012900500010165.76165.7600165.76165.761. The financial results for the quarter and year ended March 31, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 12, 2026. The Statutory Auditors have issued an unmodified audit opinion on the financial results for the year ended March 31, 2026 and have issued an unmodified conclusion in respect of limited review for the quarter ended March 31, 2026. <BR> <BR> 2. The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. <BR> <BR> 3. The consolidated financial results include results of the following wholly owned subsidiaries: <BR> (a) Neuland Laboratories Inc., USA <BR> (b) Neuland Laboratories KK., Japan. <BR> <BR> 4. Segment Reporting <BR> <BR> 5. i. Segment information presented for the "consolidated financial results" as permitted under the Ind AS - 'Operating Segments. <BR> <BR> ii. The management has assessed the identification of reportable segments in accordance with the requirements of Ind AS 108 ‘Operating Segment’ and believes that the Group has only one reportable segment namely "manufacture of active pharmaceutical ingredients and allied services”. Geography-wise details of the Company’s revenues from external customers and its non-current assets (excluding financial assets) are disclosed above. <BR> <BR> 6. During the previous year, the Company has fully transferred an investment property located in Nanakramguda, Hyderabad, Telangana, through perpetual lease, resulting in total profit of Rs. 7,640.36 lakhs (For the quarter ended June 30, 2024: Rs. 2,062.56 lakhs and for the quarter ended December 31, 2024: Rs. 5,577.80 lakhs) being the profit is exceptional in nature, it has been disclosed as a separate line item. <BR> <BR> 7. The EPS for quarters has not been annualised. <BR> <BR> 8. The Board of Directors has recommended a final dividend of Rs. 34/- (Rupees Thirty Four) only per equity share of Rs. 10 each subject to approval of shareholders for the year ended March 31, 2026. <BR> <BR> 9. The figures for the quarter ended March 31, 2026 and March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year and published unaudited figures upto nine months of the relevant financial year.2025-04-012026-03-31AuditedConsolidated202298540003016620002053151600081976450000-64262300034114140002394740009173950003518440000156417450004889771000048897710001289554000-397670001249787000036399840000000363998400010641000365062500036399840000365062500001290050001018607335000283.71283.7100283.71283.71Manufacturing expense517222000Other expenses494350000Manufacturing expense1916144000Other expenses16022960008922876000209499000002794610000518120001084600000198220000011948100013930300004556520001447008900051028640000541353100076670400027829450000433810009006561000072186300014831288000002930137700012900500018615724000187447290000187447290001609473000000996948000260642100015861100068963600003454668000356658000126429000256501200026914410001317469000436556800025317780002307800018155600007101980000001055664800029301377000Security deposits119481000Prepaid expenses1577000Capital advances412111000Balances with government authorities2337000Income Tax Assets (Net)39627000Interest accrued on bank deposits31653000Unbilled revenue11728000Prepaid expenses139791000Advance to suppliers114516000Balances with government authorities393324000Export benefits receivable74038000Other advances194000Lease Liability996948000Interest accrued but not due on borrowings588000Interest accrued on micro enterprises and small enterprises payable587000Unclaimed dividends2328000Capital creditors310948000Employee benefits payable389185000Accrual for expenses564190000Lease Liability49643000Advance from customers2445005000Liability towards Corporate Social Responsibility ('CSR') expenditure1383000Statutory liabilities85390000239474000-1245295000-22421180000-29148000852000-71829000-6745000-3400001614910000173918100009173950000210600086552000191069000013495000010055400000000-432760000-3876900004502081000000103527700003466804000000000009263000390167700000058798000010846000000002652374000150000000000000860740000-1513719000-42373290000000000010560930004471780007477600015395900017042600000209754000-5607710008171000-5526000001319304000766704000Re-measurement loss on defined benefit plans6565000Equity instruments through other comprehensive income453300011098000Re-measurement loss on defined benefit plans165000Equity instruments through other comprehensive income4533000469800027930001182000Exchange differences in translating the financial statements of foreign operations40610004061000Exchange differences in translating the financial statements of foreign operations71250007125000001236600010641000AuditedtrueM S K A & Associates LLP, Chartered Accountantstrue2027-07-31